Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53

Cancer Gene Therapy
A PataerK K Hunt

Abstract

Adenoviral delivery of the p53 gene is a potential therapeutic approach for the treatment of lung cancer. Furthermore, amifostine is a cytoprotective agent and recent reports have described its potentiation of chemotherapy's antitumor activity in lung cancer. Therefore, we wished to investigate the ability of amifostine both alone and in combination with p53-based therapy to induce apoptosis, and to understand the mechanisms by which this apoptosis occurs. Using p53 null and wild-type p53 human lung cancer cells and normal human bronchial epithelial cells, we evaluated the effects of amifostine on proliferation and apoptosis. We then analyzed Adp53 in combination with amifostine and performed isobologram analysis. Expression of p53, p21(WAF1), Bax, Bak, bcl-2, as well as total and phosphorylated Cdc2 in the absence and presence of olomoucine, a phosphorylated Cdc2 kinase inhibitor, was then determined. Amifostine-induced apoptosis in human lung cancer cells in a dose-dependent fashion. The combination of amifostine and Adp53 significantly enhanced, with a supra-additive effect, the inhibition of proliferation of lung cancer cells. This enhancement of apoptosis by amifostine was associated with activation of p53 and dephosphoryl...Continue Reading

References

Jan 1, 1979·International Journal of Radiation Oncology, Biology, Physics·G G Steel, M J Peckham
Apr 1, 1987·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D GloverD Guerry
Jul 7, 1995·Science·S J MartinD R Green
Feb 1, 1995·Molecular and Cellular Biology·R FotedarA Fotedar
Feb 25, 1994·Science·L ShiA H Greenberg
Jun 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J H SchillerW Berry
Jul 17, 1998·British Journal of Cancer·H S LiuY I Chou
May 18, 1999·Journal of the National Cancer Institute·S G SwisherM K Waugh
May 26, 1999·The Journal of Pathology·C Prives, P A Hall
Jan 5, 2002·International Journal of Cancer. Journal International Du Cancer·David J GrdinaLuka Milas
Aug 2, 2002·Cell·Norman E Sharpless, Ronald A DePinho
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·Efstathia GiannopoulouEvangelia Papadimitriou
Aug 26, 2003·Expert Review of Anticancer Therapy·Pierre-François CartronFrançois M Vallette
Sep 1, 2004·Cellular and Molecular Life Sciences : CMLS·C AkgulS W Edwards

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis